Procaine is a synthetic local anesthetic, first developed in 1905, that once dominated medical and dental practice under the brand name Novocain. It has largely been replaced because it wears off too quickly, carries a higher risk of allergic reactions than modern alternatives, and has been outperformed in both potency and duration by drugs like lidocaine and articaine. The story of procaine’s rise and fall touches on some fascinating corners of medicine, from anti-aging pseudoscience to alternative pain therapies to European livestock regulations.
How Procaine Works and What Made It a Breakthrough
Procaine belongs to the ester class of local anesthetics. It blocks nerve signals by interfering with sodium channels in nerve cell membranes, temporarily preventing pain signals from reaching the brain. When it was synthesized by the German chemist Alfred Einhorn in 1905, it was a genuine revolution. The only local anesthetic widely available at the time was cocaine, which carried obvious problems: it was addictive, toxic at relatively low doses, and caused tissue damage at injection sites. Procaine offered numbing without euphoria or dependence, and it was far safer in the doses needed for surgery and dentistry.
For decades, procaine (sold as Novocain) was the default choice for dental procedures, minor surgeries, and spinal anesthesia. If you’ve ever heard an older relative say they went to the dentist for “a shot of Novocain,” they were talking about procaine. The name became so synonymous with dental numbing that many people still use it generically, even though actual procaine has been largely absent from dental offices since the mid-twentieth century.
Why Procaine Lost Its Place in the Clinic
Procaine’s decline happened for several overlapping reasons, but the two biggest were its short duration of action and its tendency to cause allergic reactions more often than the alternatives that came along.
On the duration front, procaine is remarkably fast in and fast out. Research on intravenous procaine found that after infusion, it disappeared from the bloodstream with an elimination half-life of roughly eight minutes, confirming that it is “a drug of limited distribution and tissue uptake with a short duration of action.”1PubMed. Pharmacokinetics of intravenous procaine infusion in humans For a dentist filling a cavity or a surgeon closing a wound, that brevity is a problem. You need the numbness to last long enough to finish the procedure without re-dosing, and procaine often didn’t cooperate. Even with the addition of epinephrine (a vasoconstrictor that slows the drug’s absorption and extends its effect), procaine’s window of useful anesthesia was noticeably shorter than what lidocaine could offer.
Lidocaine, introduced in 1948, belongs to a different chemical family: the amides. It lasts longer, penetrates tissue more effectively, and produces more reliable numbness. Once lidocaine became widely available, the practical case for procaine in most clinical settings evaporated. That said, procaine’s brevity is not always a drawback. For outpatient procedures where you want the patient to regain sensation quickly, research has noted that procaine “can be used to advantage in supplementing general anesthesia in outpatient surgery because of its brief action.”2The American Journal of Surgery. Reappraisal of intravenous procaine as a short-acting anesthetic adjuvant But those niche advantages were not enough to keep procaine at the center of mainstream practice.
The Allergy Problem
The other major strike against procaine is allergic reactions. When your body breaks down procaine, one of the byproducts is para-aminobenzoic acid, or PABA. This metabolite is a known allergen. Ester-class local anesthetics as a group are associated with a higher incidence of allergic reactions because of this PABA metabolite.3PubMed. Understanding allergic reactions to local anesthetics Reactions can range from mild skin rashes to more serious anaphylactic events, though true anaphylaxis remains rare.
Amide-class anesthetics like lidocaine, bupivacaine, and articaine do not produce PABA when metabolized, so they carry a much lower allergy risk. For clinicians, this made the choice straightforward: why use a drug that wears off faster and is more likely to trigger an allergic reaction when a safer, longer-lasting alternative sits on the same shelf? Patients with a documented allergy to procaine or other ester anesthetics can almost always safely receive an amide anesthetic instead, and most modern allergy-testing protocols reflect this ester-versus-amide distinction.
One common misconception worth addressing: many people who believe they are “allergic to Novocain” actually experienced side effects from epinephrine (the vasoconstrictor often mixed with the anesthetic), anxiety-related reactions, or vasovagal episodes that mimicked an allergic response. True immunologic allergy to local anesthetics is much less common than patients and even some clinicians assume. Still, the perception of higher allergy risk with procaine added to its decline, regardless of how many of those reported reactions were genuine allergies.
What Replaced Procaine in Dentistry
Modern dental offices primarily stock lidocaine, articaine, mepivacaine, and bupivacaine. Each has its own profile of onset speed, duration, and tissue penetration. Lidocaine became the workhorse starting in the 1950s and remains the most widely used dental anesthetic worldwide. Articaine, a newer amide anesthetic, has been gaining ground because of its superior ability to diffuse through bone, which matters for procedures on the lower jaw where the bone is thick and dense. Research comparing articaine to lidocaine for dental infiltration anesthesia found that articaine’s success rate was roughly two to three times higher than lidocaine’s for mandibular infiltration, and their adverse-reaction profiles were nearly identical.4PubMed Central. The potential of articaine as new generation of local anesthesia in dental clinics: A review
If articaine outperforms even lidocaine in certain situations, the gap between modern anesthetics and procaine is even wider. Procaine’s lower potency, shorter duration, and higher allergenicity make it essentially obsolete for routine dental work. You would be hard-pressed to find a dental office in North America or Europe that keeps procaine in its anesthetic cart today.
The Anti-Aging Controversy
One of the stranger chapters in procaine’s history has nothing to do with numbing teeth. In the 1950s and 1960s, the Romanian physician Ana Aslan developed a preparation called Gerovital H3 (GH3), which was essentially buffered procaine marketed as an anti-aging treatment. Aslan claimed that GH3 could reverse the effects of aging, improve memory, restore hair color, smooth wrinkles, and treat depression. The product attracted enormous attention, and celebrities and political figures reportedly traveled to Romania for injections.
The scientific establishment was skeptical from the start. Many of the early studies supporting Gerovital were poorly controlled, and attempts to replicate the dramatic anti-aging claims in rigorous trials largely failed. However, the story did not end there. A 2021 review examined decades of research on procaine’s biological effects and found that the molecule does interact with multiple cellular pathways related to oxidative stress, inflammation, DNA damage, and methylation.5PubMed Central. Procaine-The Controversial Geroprotector Candidate: New Insights Regarding Its Molecular and Cellular Effects In laboratory and animal models, procaine has shown antioxidant properties and some capacity to modulate age-related cellular damage.
That sounds promising on the surface, but “shows effects in a lab dish” and “reverses human aging” are separated by an enormous gap. Many substances that look protective in cell cultures do nothing useful when given to a living person. The review itself characterized procaine as a “controversial geroprotector candidate,” which is a polite way of saying the jury is still very much out. No credible medical body recommends procaine as an anti-aging therapy, and the Gerovital H3 era is generally regarded as a cautionary tale about how charismatic clinical claims can outrun actual evidence. Still, the fact that researchers continue to probe procaine’s cellular effects suggests the molecule isn’t completely uninteresting from a biological standpoint, even if the grand anti-aging narrative was overblown.
Neural Therapy and Complementary Medicine
While procaine has faded from mainstream medicine, it remains a central tool in a practice called neural therapy. This approach, developed in Germany in the early twentieth century, involves injecting small amounts of procaine (or occasionally lidocaine) into specific sites on the body: scars, trigger points, acupuncture points, or areas near autonomic nerve ganglia. Practitioners claim that these injections can resolve chronic pain, organ dysfunction, and even emotional disturbances by “resetting” disrupted nerve patterns. Neural therapy has a modest following in parts of Europe, Latin America, and among some integrative medicine practitioners in North America.
Qualitative research on patients undergoing neural therapy reported a sequence of experiences: first, the expected local anesthetic effects like temporary pain blocking and warmth; second, vegetative reactions that sometimes included initial worsening of symptoms or the surfacing of previously hidden symptoms; and third, for many patients, physical and emotional release along with improvements in symptoms and mood.6PubMed Central. Emotional release and physical symptom improvement: a qualitative analysis of self-reported outcomes and mechanisms in patients treated with neural therapy These are self-reported outcomes, not findings from a controlled trial, so they should be interpreted cautiously. The mechanisms proposed by neural therapy practitioners do not align well with current mainstream neuroscience, and high-quality evidence for most of its specific claims remains thin.
Why procaine specifically for neural therapy, rather than lidocaine? Proponents argue that procaine’s rapid breakdown and PABA metabolite actually offer advantages in this context: the anesthetic effect is brief, and PABA itself may have mild vasodilatory and other local effects that practitioners consider therapeutically useful. Whether those theoretical advantages hold up under scrutiny is debatable, but it explains why procaine persists in a corner of medicine where most other practitioners have moved on.
Procaine in Veterinary Medicine
There is one area where procaine has found renewed relevance, and it has nothing to do with human patients. Within the European Union, lidocaine use in food-producing animals is restricted because of concerns about drug residues entering the human food supply. This regulatory reality has sent veterinarians looking for alternatives, and procaine, with its rapid metabolism and long safety track record, has reemerged as a practical option.
A recent study compared procaine (with and without epinephrine) to lidocaine for pain control during calf disbudding, a common and painful livestock procedure. The results indicated that procaine combined with epinephrine was a safe and effective alternative to lidocaine for this purpose.7PubMed Central. Efficacy of Procaine, With and Without Epinephrine, Compared to Lidocaine in Local Anesthesia for Calves Before Thermocautery Disbudding The same rapid metabolism that makes procaine less useful in a dental chair becomes an advantage in livestock: the drug clears the animal’s system quickly, reducing the risk of residues in meat or milk.
Procaine also continues to play a role in veterinary medicine through procaine penicillin G, a formulation where procaine is combined with the antibiotic penicillin. In this pairing, procaine acts as a carrier that slows the release of penicillin from the injection site, creating a depot effect that extends the antibiotic’s duration. Procaine penicillin G remains widely used in cattle, horses, sheep, and other livestock for bacterial infections. It is one of the most commonly administered injectable antibiotics in agricultural veterinary practice worldwide.
Procaine Penicillin and the Drug Interaction Question
Because procaine penicillin remains in active veterinary and occasional human use, its interactions with other drugs still matter. Early pharmacological research examined whether procaine penicillin could be safely given alongside sulfonamide antibiotics, another class of antimicrobial drugs. The findings showed that procaine penicillin could be administered with several common sulfonamides, including sulfadiazine and sulfathiazole, without problems, but it appeared to be antagonistic toward sulfanilamide specifically.8Journal of the American Pharmaceutical Association. Procaine Penicillin and Sulfonamide Antagonism In practical terms, this means that combining procaine penicillin with certain older sulfonamides could reduce the effectiveness of one or both drugs. Modern prescribing guidelines take these interactions into account, though the specific combination is uncommon today given the availability of newer antibiotics.
Where You Might Still Encounter Procaine
Despite being largely retired from everyday clinical practice, procaine has not disappeared entirely. Beyond neural therapy and veterinary medicine, it occasionally turns up in a few other contexts. Some compounding pharmacies prepare procaine-based solutions for specific patient needs when amide anesthetics are contraindicated, though this is uncommon. In parts of Eastern Europe and Latin America, preparations derived from the Gerovital H3 tradition are still available, marketed as nutritional supplements or wellness products rather than pharmaceuticals. These products occupy a regulatory gray area in most countries and are not endorsed by mainstream medical organizations.
Procaine is also still used as a research tool. Its well-understood pharmacology, rapid clearance, and long history of documentation make it a convenient reference compound in studies of local anesthetic mechanisms, nerve conduction, and cellular pharmacology. Researchers investigating how local anesthetics interact with ion channels, cell membranes, or inflammatory pathways frequently include procaine as a comparator or control agent. In that sense, procaine’s long clinical history has given it a second life as a standard reference molecule in laboratory science, even as practicing clinicians have set it aside.
The broader lesson of procaine’s trajectory is about how quickly a once-dominant drug can be displaced when better options emerge. Procaine was not pulled from the market for being dangerous. It simply became outclassed. Lidocaine offered longer, more reliable numbing with fewer allergic reactions. Articaine pushed the performance envelope even further for dental work. Bupivacaine provided extended anesthesia for surgical and obstetric procedures. Each new entrant nibbled away at the clinical territory procaine had held, until there was almost no scenario left where procaine was the best available choice for a human patient. For a drug that once defined modern local anesthesia, that’s a humbling but instructive arc.